<DOC>
	<DOCNO>NCT01235273</DOCNO>
	<brief_summary>The objective study determine whether treatment low IGF-1 syndrome patient CHF able modify functional parameter , recognize valid surrogate end-points CHF progression .</brief_summary>
	<brief_title>Treatment lOw IGF-1 Syndrome aSsociated With Chronic Heart fAilure : A Randomized , Placebo-Controlled , Double-Blind Study .</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>patient either sex affect CHF NYHA class IIIII , secondary ischemic idiopathic dilate cardiomyopathy age range 3080 year stable medication least two month prior randomization , include ACE inhibitor AT1 antagonists betablockers ( unless untolerated ) . LV ejection fraction 40 % less Peak VO2 consumption CPET â‰¤ 16 ml/kg/min . LV enddiastolic dimension 55 mm low IGF1 level satisfactory response IGF1 generation test inform consent haemodynamic clinically significant primary valvular disease significant congenital heart disease acute pericarditis/myocarditis inability perform bicycle exercise test Poorly control diabetes mellitus ( HbA1c &gt; 8.5 ) active proliferative severe nonproliferative diabetic retinopathy active and/or history malignancy evidence progression recurrence underlie intracranial tumor unstable angina recent myocardial infarction ( le 5 month ) severe liver disease serum creatinine level &gt; 2.5 mg/dl Inability cooperate administer study drug Patients participate clinical study , within 30 day prior screen visit and/or particular study period</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>